Biotechnologies and the future of opioid addiction treatments.

  title={Biotechnologies and the future of opioid addiction treatments.},
  author={Daniel Wolfe and Roxanne Saucier},
  journal={The International journal on drug policy},
1 Citations
A Prospective Three-Months Naturalistic Follow-Up Study of Outcomes of Patients with Opioid Dependence Discharged on Buprenorphine or Oral Naltrexone
It is suggested that retention outcomes may vary between naltrexone and buprenorphine, though both medications may improve several patient-related parameters, while the physical and psychological quality of life improved in both the groups.


Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
The clinical pharmacology of these products and their expected clinical advantages for the manufacturers, clinicians, policy makers and patients are reviewed, and their perspective is offered, as clinicians and researchers, on how things can improve.
Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary
The social control mechanisms that are imposed in MAT are strikingly similar to those reflected in criminal justice settings, namely probation, parole and community corrections more generally and how they are monitored, tracked, and controlled have major implications for recovery.
Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
All potential patients should be offered accessible information on depot buprenorphine to enable them to consider their options and participate meaningfully in treatment decision making, and it is recommended that further qualitative research is undertaken to produce informative video material that describes patient experiences of receiving depot buenorphine.
Efficacy of Invasive and Non-Invasive Brain Modulation Interventions for Addiction
To establish the potential of neuromodulation for addiction, more randomized controlled trials are needed that also investigate treatment duration required for long-term abstinence and potential synergy with other addiction interventions.
Disciplining Addictions: The Bio-politics of Methadone and Heroin in the United States
  • P. Bourgois
  • Psychology
    Culture, medicine and psychiatry
  • 2000
An ethnographic perspective on the ways street-based heroin addicts experience methadone reveals the quagmire of powerrelations that shape drug treatment in the United States.
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
It is demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder.
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments, and strategies to address the underuse of MOUD are needed.
An Oxycodone Conjugate Vaccine Elicits Drug-Specific Antibodies that Reduce Oxycodone Distribution to Brain and Hot-Plate Analgesia
In rats given a single intravenous dose of OXY, immunization with OXY(Gly)4-KLH increased OXY protein binding and retention in serum while decreasing its unbound (free) concentration in plasma and distribution to brain.